Clinical Trial Update: Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating nitric oxide during cardiopulmonary bypass in neonates to reduce acute kidney injury has been withdrawn after Phase 2/3 designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Kidney Injury

Drugs mentioned

• Nitric Oxide (nitric oxide)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Acute Kidney Injury, Congenital Heart Disease | Phase 2, Phase 3 | Status: WITHDRAWN